One biology. Two frontiers.
Across a range of degenerative diseases, the same underlying failures recur: chronic inflammation, impaired cellular quality control, and reduced regenerative capacity. In a premature baby, these processes can destroy the intestine within days; in adults, they can drive the gradual deterioration of many tissues over decades.
Micregen has developed Secretomix®, a cell-free therapeutic platform built from what stem cells release rather than from the cells themselves, designed to address these shared mechanisms across multiple diseases.
Built upon 20 years of prior academic research, Micregen has completed 10 years of preclinical work, developed proprietary GMP cell banks and manufacture of clinical-grade material is now ready to begin.
Despite substantial advances in neonatal care, mortality in Necrotising Enterocolitis (NEC) has seen little meaningful improvement, and there is still no approved pharmacological therapy indicated to prevent or treat it.
Severe NEC kills up to half the premature infants who develop it. Available treatment today is antibiotics, bowel rest and surgery. There is no medicine that stops it and mortality from severe NEC has little changed in decades.
Our lead Secretomix® candidate, MRG1061, aims to overcome these hurdles. It has been designed to interrupt the inflammatory cascade and support the intestinal tissue to repair. It has shown a statistically significant reduction in NEC lesion severity in pre-clinical models, conducted at The Hospital for Sick Children (SickKids), Toronto and Great Ormond Street Hospital, London.
Independent characterisation of MRG1061 has identified 566 microRNA species and 1,907 proteins acting across 140 enriched biological pathways. In preclinical work, that cargo has also been shown to act on four of the recognised hallmarks of ageing.
Establishing the mechanism in NEC does not only serve NEC. It provides a clinical and manufacturing foundation for evaluating the platform in additional indications, such as inflammatory bowel disease, COPD, neurodegeneration and healthy ageing.
efficacy demonstrated across four institutions in three countries, including NEC and BPD models conducted by third-party academic centres
The foundations are in place. The manufacturing route is established, with partners identified and ready to contract. The regulatory pathway is open. Micregen is positioned to manufacture clinical-grade material and take MRG1061 into its first-in-human trial in NEC.
We are talking to investors who believe in impact investing and want to fund that step. We are also talking to pharma partners who want to license the platform once initial safety and efficacy human data are in hand.
The longevity applications are held separately, under Anageria™, and are now available to a dedicated partner.